Potassium Phosphates
Loading...Potassium Phosphates Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
Potassium Phosphates Injection must be diluted and thoroughly mixed before use.
To avoid potassium or phosphorus intoxication, infuse solutions containing potassium phosphates slowly. In patients with severe renal or adrenal insufficiency, administration of Potassium Phosphates Injection may cause potassium intoxication. Infusing high concentrations of phosphorus may cause hypocalcemia, and calcium levels should be monitored.
Solutions which contain potassium ions should be used with great care if at all, in patients with hyperkalemia, severe renal failure and in conditions in which potassium retention is present.
In patients with diminished renal function, administration of solutions containing potassium ions may result in potassium retention.
This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particulary at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.
Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.
Legal Issues
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
Manufacturer Warnings
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Uses
Potassium Phosphates Injection, USP, 3 mM P/mL, is indicated as a source of phosphorus, for addition to large volume intravenous fluids, to prevent or correct hypophosphatemia in patients with restricted or no oral intake. It is also useful as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions. The concomitant amount of potassium (4.4 mEq/mL) must be calculated into total electrolyte content of such prepared solutions.
History
There is currently no drug history available for this drug.
Other Information
Potassium Phosphates Injection, USP is a sterile, nonpyrogenic, concentrated solution containing a mixture of monobasic and dibasic potassium phosphate in Water for Injection. It must be diluted prior to administration.
Each mL of the solution consists of two phosphate salts provided as follows:
| Ingredient(s) | Phosphorus | Potassium |
| Monobasic Potassium | 93 mg | 170 mg |
| Phosphate -224 mg | ||
| Anhydrous | or | or |
| Dibasic Potassium | ||
| Phosphate -236 mg | 3 mM | 4.4 mEq |
| Anhydrous |
The solution contains no bacteriostatic agent or other preservative.
The solution is intended to provide phosphate ion, (PO4-3) for addition to large volume infusion fluids for intravenous use. Unused portions should be discarded.
Sources
Potassium Phosphates Manufacturers
-
American Regent, Inc.
![Potassium Phosphates (Potassium Phosphate, Monobasic And Potassium Phosphate, Dibasic) Injection, Solution [American Regent, Inc.]](/wp-content/themes/bootstrap/assets/img/loading2.gif)
Potassium Phosphates | American Regent, Inc.
Potassium Phosphates Injection is administered intravenously only after dilution in a larger volume of fluid. The dose and rate of administration are dependent upon the individual needs of the patient. Serum potassium, inorganic phosphorus and calcium levels should be monitored as a guide to dosage.
Withdraw the calculated volume aseptically and transfer to appropriate intravenous fluid to provide the desired number of millimoles (mM) of phosphorus and milliequivalents (mEq) of potassium.
-
Fresenius Kabi Usa, Llc
Potassium Phosphates | Fresenius Kabi Usa, Llc
Potassium phosphates is administered intravenously only after dilution in a larger volume of fluid. The dose and rate of administration are dependent upon the individual needs of the patient. Serum potassium, inorganic phosphorus and calcium levels should be monitored as a guide to dosage.
Withdraw the calculated volume aseptically and transfer to appropriate intravenous fluid to provide the desired number of millimoles (mmol) of phosphate and milliequivalent (mEq) of Potassium (K+).
-
Hospira, Inc.
Potassium Phosphates | Hospira, Inc.
Potassium Phosphates Injection, USP 3 mM P/mL is administered intravenously only after dilution in a larger volume of fluid. The dose and rate of administration are dependent upon the individual needs of the patient. Serum potassium, inorganic phosphorus and calcium levels should be monitored as a guide to dosage. Using aseptic technique, all or part of the contents of one or more vials may be added to other intravenous fluids to provide any desired number of millimoles (mM) of phosphorus.
In adult patients receiving TPN (total parenteral nutrition), a dose of 12 to 15 mM phosphorus is recommended for each 500 mL of 50% Dextrose Injection, USP administered. The amount of potassium which accompanies the addition of phosphorus as potassium phosphate also should be kept in mind and if necessary, serum potassium levels and/or electrocardiographic changes should be monitored.
The suggested dose of phosphorus for infants receiving TPN is 1.5 to 2 mM P/kg/day.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
See PRECAUTIONS. -
Hospira, Inc.
Potassium Phosphates | Hospira, Inc.
Potassium Phosphates Injection, USP 3 mM P/mL is administered intravenously only after dilution in a larger volume of fluid. The dose and rate of administration are dependent upon the individual needs of the patient. Serum potassium, inorganic phosphorus and calcium levels should be monitored as a guide to dosage. Using aseptic technique, all or part of the contents of one or more vials may be added to other intravenous fluids to provide any desired number of millimoles (mM) of phosphorus.
In adult patients receiving TPN (total parenteral nutrition), a dose of 12 to 15 mM phosphorus is recommended for each 500 mL of 50% Dextrose Injection, USP administered. The amount of potassium which accompanies the addition of phosphorus as potassium phosphate also should be kept in mind and if necessary, serum potassium levels and/or electrocardiographic changes should be monitored.
The suggested dose of phosphorus for infants receiving TPN is 1.5 to 2 mM P/kg/day.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
See PRECAUTIONS.
![Potassium Phosphates (Potassium Phosphate, Monobasic And Potassium Phosphate, Dibasic) Injection, Solution [Fresenius Kabi Usa, Llc]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e7d6dfe1-d8ad-4daf-9c6a-5f42e3e19138&name=potassium-phosphates-injection-usp-figure-2-8650-vial.jpg)
![Potassium Phosphates (Potassium Phosphate, Monobasic And Potassium Phosphate, Dibasic) Injection, Solution, Concentrate [Hospira, Inc.]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0e359fe-a90b-44e2-960c-cd82babc4f4c&name=potassium-phosphates-injection-usp3-figure-1-ca-0764.jpg)
![Potassium Phosphates (Potassium Phosphate, Monobasic And Potassium Phosphate, Dibasic) Injection, Solution, Concentrate [Hospira, Inc.]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=fe906590-eb37-4a1a-9367-42106e66cbe9&name=potassium-phosphates-injection-usp2-figure-1-ca-2338.jpg)
Login To Your Free Account